Case study - Keranova


  • >15
  • 2016
    Creation Date & Investment Year
  • France
  • Mérieux Participations 2
    Fund Name
  • In Portfolio
  • Valérie Calenda
    Board Director

Company profile

KERANOVA is a fast-growing start-up developing a breakthrough ophthalmologic technology. They design and develop robotic surgical equipment for various diseases of the anterior segment of the eye.  The company is using a unique patented technology that represents a major advance in ophthalmologic surgical procedures. 

KERANOVA’s first device addressed cataracts and could tackle refractory problems, such as myopia and astigmatism. This innovative approach protected by 11 patent families provides a rethinking of surgical procedures and reduces manual procedures in favour of automation and precision. The device has been successfully validated in a first in human study. 

Investment thesis

Our investment was motivated by:

  • A company with a pre-clinically proven disruptive technology, a strong IP portfolio and an “A” team
  • A sector where stakeholders are in search for a technological leap

Added value by MxEP

Since its initial investment in 2016, MxEP has provided support on several fronts such as:

  • Leverage our network to expand the team and build an international SAB
  • Leverage synergies with another portfolio company (femtolaser manufacturer)  
  • Support the management on building regulatory and clinical strategy for the US market
  • Discuss several options for Series B fund raising
  • Prepare a “build to buy” deal with management

MxEP was instrumental in helping us refine our business model and roadmaps […] and an invaluable partner in the financing process but also in the day-to-day development of our business by opening up their network of experts to us and by supporting us through all the key stages with a cooperative approach.